

HOLLIS EDEN PHARMACEUTICALS INC /DE/  
Form SC 13G/A  
July 15, 2005

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED  
PURSUANT TO RULES 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO  
FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1)\*

Hollis-Eden Pharmaceuticals, Inc.

-----  
(Name of Issuer)

Common Stock, par value \$0.01 per share

-----  
(Title of Class of Securities)

435902101

-----  
(CUSIP Number)

July 15, 2005

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP NO. 435902101

Page 2 of 8

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Cranshire Capital, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

3 SEC USE ONLY

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G/A

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF 5 SOLE VOTING POWER

SHARES N/A

BENEFICIALLY 6 SHARED VOTING POWER

OWNED BY N/A

EACH 7 SOLE DISPOSITIVE POWER

REPORTING N/A

PERSON 8 SHARED DISPOSITIVE POWER

WITH N/A

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

N/A

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[X]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 5%

12 TYPE OF REPORTING PERSON

PN

SCHEDULE 13G

CUSIP NO. 435902101

Page 3 of 8

1 NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Downsview Capital, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]

(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF 5 SOLE VOTING POWER

SHARES N/A

BENEFICIALLY 6 SHARED VOTING POWER

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G/A

OWNED BY N/A  
-----  
EACH 7 SOLE DISPOSITIVE POWER  
REPORTING N/A  
-----  
PERSON 8 SHARED DISPOSITIVE POWER  
WITH N/A  
-----

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
N/A  
-----

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
[X]  
-----

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
Less than 5%  
-----

12 TYPE OF REPORTING PERSON  
CO  
-----

SCHEDULE 13G

CUSIP NO. 435902101

Page 4 of 8

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)  
Mitchell P. Kopin  
-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [ ]  
-----

3 SEC USE ONLY  
-----

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
U.S.A.  
-----

NUMBER OF 5 SOLE VOTING POWER  
SHARES N/A  
-----

BENEFICIALLY 6 SHARED VOTING POWER  
OWNED BY N/A  
-----

EACH 7 SOLE DISPOSITIVE POWER  
REPORTING N/A  
-----

PERSON 8 SHARED DISPOSITIVE POWER  
WITH N/A  
-----

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G/A

N/A

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[X]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 5%

12 TYPE OF REPORTING PERSON

IN

SCHEDULE 13G

CUSIP NO. 435902101

Page 5 of 8

Item 1(a). Name of Issuer:

Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

4435 Eastgate Mall, Suite 400  
San Diego, California 92121

Items 2(a), (b) and (c). Name of Persons Filing, Address of Principal Business Office and Citizenship:

This Amendment No. 1 to Schedule 13G is being filed on behalf of (i) Cranshire Capital, L.P., an Illinois limited partnership ("Cranshire"), (ii) Downsvieview Capital, Inc., an Illinois corporation ("Downsvieview") and (iii) Mitchell P. Kopin, an individual who is a citizen of the U.S.A. ("Kopin," together with Cranshire and Downsvieview, the "Reporting Persons").

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Amendment No. 1 to Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Amendment No. 1 to Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of each of the Reporting Persons is 666 Dundee Road, Suite 1901, Northbrook, Illinois, 60062.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.01 per share, of the Issuer (the "Common Stock")

Item 2(e). CUSIP Number:

435902101

Item 3. Not applicable.

Item 4. Ownership.

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G/A

- (a) Amount beneficially owned: N/A
- (b) Percent of class: Less than 5%
- (c) Number of shares to which such person has:
  - (i) Sole power to vote or direct the vote: N/A
  - (ii) Shared power to vote or direct the vote: N/A

SCHEDULE 13G

CUSIP NO. 435902101

Page 6 of 8

- (iii) Sole power to dispose or to direct the disposition of:  
N/A
- (iv) Shared power to dispose of or direct the disposition  
of: N/A

The beneficial ownership of the Reporting Persons excludes certain shares of Common Stock issuable upon the exercise of warrants held by Cranshire. Such warrants issued to Cranshire contain exercise caps which prohibit the holder of the warrants from exercising such warrants to the extent that giving effect to such exercise, such holder would beneficially own in excess of 4.99% of the Issuer's outstanding Common Stock (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following |X|.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of a Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G/A

participant in any transaction having that purpose or effect.

SCHEDULE 13G

CUSIP NO. 435902101

Page 7 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 15, 2005

CRANSHIRE CAPITAL, L.P.

By: Downsvew Capital, Inc.,  
its general partner

By:/s/ Mitchell P. Kopin  
-----  
Mitchell P. Kopin, President

DOWNSVIEW CAPITAL, INC.

By:/s/ Mitchell P. Kopin  
-----  
Mitchell P. Kopin, President

/s/ Mitchell P. Kopin  
-----  
Mitchell P. Kopin

SCHEDULE 13G

CUSIP NO. 435902101

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of Common Stock of Hollis-Eden Pharmaceuticals, Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided, however, that no party is responsible for the completeness or accuracy of the information concerning any other party making the filing, unless such party knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement on July 15, 2005.

CRANSHIRE CAPITAL, L.P.

By: Downsvew Capital, Inc.,

its general partner

By:/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin, President

DOWNSVIEW CAPITAL, INC.

By:/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin, President

/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin